Focus remains on advancing pipeline across cannabinoid and spray platforms
PHOENIX, Aug. 08, 2018 (GLOBE NEWSWIRE) -- INSYS Therapeutics, Inc. (NASDAQ: INSY), a leader in the development, manufacture and commercialization of pharmaceutical cannabinoids (CBD) and spray technology, today reported financial results for its second quarter ended June 30, 2018.
“Our continuing commitment to the potential of CBD and our nasal spray technology to significantly improve the lives of patients was highlighted by several important milestones in the second quarter of 2018, as we continue to make progress against our strategic plan,” said Saeed Motahari, president and chief executive officer of INSYS Therapeutics. “We received encouraging results from our pharmacokinetics study of epinephrine nasal spray and initiated a Phase 2 study of CBD for Prader-Willi Syndrome. Furthermore, we believe we remain on track to submit an NDA for naloxone nasal spray by the end of 2018. These critical milestones are in keeping with our long-term goal to submit one NDA per year through 2021.”
Motahari continued, “Prescriptions for our primary commercial product, SUBSYS®, declined at a slower rate than the overall TIRF market in the second quarter. Our commercial efforts are showing signs of traction, as we gained prescription share in the TIRF market sequentially for the first time in seven quarters. These efforts include new managed care wins, patient education, upgrading the salesforce talent and optimizing territory alignment.”
Motahari added, “Albeit off a small base, prescriptions of SYNDROS® experienced a solid improvement in the second quarter as net revenue improved 56 percent sequentially, driven by the initial success of our patient access and educational programs. We remain resolute in our commitment to patients who rely on SYNDROS® and SUBSYS® and believe our product pipeline has the potential to significantly improve the lives of patients with unmet medical needs—particularly our two life-saving drug candidates, epinephrine and naloxone nasal sprays.”
Financial & Operating Highlights
A conference call is scheduled for 5:00 p.m. Eastern Standard Time on Aug. 8, 2018, to discuss the financial and operational results for the second quarter 2018. Interested parties can listen to the call live as it occurs via the company’s website, https://www.insysrx.com/, on the Investors section’s Presentations & Events page; or by dialing 844-263-8304 (from inside the U.S.) or 213-358-0958 (from outside the U.S.), and using the Conference ID 2070039. A webcasted replay of the call will be available on the site a few hours after the event.
INSYS Therapeutics is a specialty pharmaceutical Company that develops and commercializes innovative drugs and novel drug delivery systems of therapeutic molecules that improve patients’ quality of life. Using proprietary spray technology and capabilities to develop pharmaceutical cannabinoids, INSYS is developing a pipeline of products intended to address unmet medical needs and the clinical shortcomings of existing commercial products. INSYS is committed to developing medications for potentially treating anaphylaxis, epilepsy, Prader-Willi syndrome, opioid addiction and overdose, and other disease areas with a significant unmet need.
SUBSYS® and SYNDROS® are trademarks of INSYS Development Company, Inc., a subsidiary of INSYS Therapeutics, Inc.
NOTE: All trademarks and registered trademarks are the property of their respective owners.
This news release contains forward-looking statements, including discussions about stabilizing and generating future revenue, our future leadership position in the use of cannabinoids to develop potential solutions for patients in need and expectation around research and clinical product development and our expectations around our pipeline products including timelines and results related thereto. These forward-looking statements are based on management’s expectations and assumptions as of the date of this news release; actual results may differ materially from those in these forward-looking statements as a result of various factors, many of which are beyond our control. These factors include, but are not limited to, risk factors described in our filings with the United States Securities and Exchange Commission, including those factors discussed under the caption “Risk Factors” in our Annual Report on Form 10-K for the year ended Dec. 31, 2017 and subsequent updates that may occur in our Quarterly Reports on Form 10-Q. Forward-looking statements speak only as of the date of this news release, and we undertake no obligation to publicly update or revise these statements, except as may be required by law.
Non-GAAP Financial Measures
In addition to reporting all financial information required in accordance with generally accepted accounting principles (GAAP), the Company is also reporting Adjusted EBITDA, Adjusted net loss and Adjusted net loss per diluted share, which are non-GAAP financial measures. Since Adjusted EBITDA, Adjusted net loss and Adjusted net loss per diluted share are not GAAP financial measures, they should not be used in isolation or as a substitute for consolidated statements of comprehensive loss and cash flow data prepared in accordance with GAAP. In addition, the Company’s definitions of Adjusted EBITDA, Adjusted net loss and Adjusted net loss per diluted share may not be comparable to similarly titled non-GAAP financial measures reported by other companies. For a full reconciliation of Adjusted EBITDA and Adjusted net loss to GAAP net income, please see the attachments to this earnings release.
Adjusted EBITDA, as defined by the Company, is calculated as follows:
Net loss, plus:
The Company believes that Adjusted EBITDA can be a meaningful indicator, to both Company management and investors, of the past and expected ongoing operating performance of the Company. EBITDA is a commonly used and widely accepted measure of financial performance. Adjusted EBITDA is deemed by the Company to be a useful performance indicator because it includes an add-back of non-cash and non-recurring operating expenses that may be subject to uncontrollable factors not reflective of the Company’s true operational performance.
Adjusted net loss, as defined by the Company, is calculated as follows:
Net loss, plus:
Adjusted net loss per diluted share is equal to Adjusted net loss divided by the diluted share count for the applicable period.
The Company believes that Adjusted net loss and Adjusted net loss per diluted share are meaningful financial indicators, to both Company management and investors, in that they exclude non-cash income and expense items, as well as other income and expense items that are not expected to recur and therefore are not reflective of continuing operating performance.
While the Company uses Adjusted EBITDA, Adjusted net loss and Adjusted net loss per diluted share in managing and analyzing its business and financial condition and believes these non-GAAP financial measures to be useful to investors in evaluating the Company’s performance, each of these financial measures has certain shortcomings. Adjusted EBITDA does not take into account the impact of capital expenditures on either the liquidity or the GAAP financial performance of the Company and likewise omits share-based compensation expenses, which may vary over time and may represent a material portion of overall compensation expense. Adjusted net loss does not take into account non-cash expenses that reflect the amortization of past expenditures, or include stock-based compensation, which is an important and material element of the Company’s compensation package for its directors, officers and other key employees. As a result of the inherent limitations of each of these non-GAAP financial measures, the Company’s management utilizes comparable GAAP financial measures to evaluate the business in conjunction with Adjusted EBITDA, Adjusted net loss and Adjusted net loss per diluted share and encourages investors to do likewise.
— Financial tables follow —
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS(In thousands, except share and per share amounts)(unaudited) Three Months Ended June 30, Six Months Ended June 30, 2018 2017 2018 2017 Net revenue$ 23,466 $ 42,576 $ 47,377 $ 78,538 Cost of revenue 3,596 3,921 5,800 8,560 Gross profit 19,870 38,655 41,577 69,978 Operating expenses: Sales and marketing 9,079 13,292 18,130 28,950 Research and development 16,473 14,103 28,733 27,037 General and administrative 10,875 10,643 20,427 20,573 Legal 11,148 6,483 21,485 11,595 Charges related to litigation award and settlements - 4,450 740 4,450 Total operating expenses 47,575 48,971 89,515 92,605 Loss from operations (27,705) (10,316) (47,938) (22,627)Interest income 484 465 987 900 Other income (expense),net (3) 13 (472) 39 Loss before income taxes (27,224) (9,838) (47,423) (21,688)Income tax expense (benefit) 126 (1,654) 297 (6,980)Net loss$ (27,350) $ (8,184) $ (47,720) $ (14,708) Net loss per common share: Basic$ (0.37) $ (0.11) $ (0.65) $ (0.20) Diluted$ (0.37) $ (0.11) $ (0.65) $ (0.20) Shares used in computing net loss per common share: Basic 73,920,645 72,169,361 73,832,924 72,057,552 Diluted 73,920,645 72,169,361 73,832,924 72,057,552 Percentage of Net revenue: Net revenue 100.0% 100.0% 100.0% 100.0%Cost of revenue 15.3% 9.2% 12.2% 10.9%Gross profit 84.7% 90.8% 87.8% 89.1% Operating expenses: Sales and marketing 38.7% 31.2% 38.3% 36.9% Research and development 70.2% 33.1% 60.6% 34.4% General and administrative 46.4% 25.0% 43.2% 26.1% Legal 47.6% 15.2% 45.3% 14.8% Charges related to litigation award and settlements 0.0% 10.5% 1.6% 5.7%Total operating expenses 202.9% 115.0% 189.0% 117.9% Loss from operations -118.2% -24.2% -101.2% -28.8%Interest income 2.1% 1.1% 2.1% 1.1%Other income (expense),net 0.0% 0.0% -1.0% 0.1%Loss before income taxes -116.1% -23.1% -100.1% -27.6%Income tax expense (benefit) 0.5% -3.9% 0.6% -8.9%Net loss -116.6% -19.2% -100.7% -18.7%
INSYS THERAPEUTICS, INC.CONDENSED CONSOLIDATED BALANCE SHEETS(In thousands)(unaudited) June 30, December 31, 2018 2017ASSETS: Cash and cash equivalents$ 16,090 $ 31,999Short-term investments 88,813 85,189Accounts receivable, net 20,067 21,513Inventories 10,001 17,408Prepaid expenses and other current assets 21,143 19,833Long-term investments 18,605 46,733Other non-current assets 60,426 56,405Total assets$ 235,145 $ 279,080 LIABILITIES AND STOCKHOLDERS' EQUITY: Liabilities$ 210,508 $ 215,798Stockholders' equity 24,637 63,282Total liabilities and stockholders' equity$ 235,145 $ 279,080
INSYS THERAPEUTICS, INC.RECONCILIATION OF NET LOSS TO NON-GAAP ADJUSTED EBITDA(In thousands)(unaudited) Three Months Ended June 30, Six Months Ended June 30, 2018 2017 2018 2017 Net loss$ (27,350) $ (8,184) $ (47,720) $ (14,708)Adjustments to arrive at EBITDA: Interest income (484) (465) (987) (900) Income tax expense (benefit) 126 (1,654) 297 (6,980) Depreciation and amortization expense 1,813 1,914 3,751 3,688 EBITDA (25,895) (8,389) (44,659) (18,900) Non-cash stock compensation expense 3,384 4,288 6,554 8,280 Charges related to litigation award and settlements - 4,450 740 4,450 Adjusted EBITDA$ (22,511) $ 349 $ (37,365) $ (6,170)
INSYS THERAPEUTICS, INC.RECONCILIATION OF NET LOSS TO NON-GAAP ADJUSTED NET LOSS(In thousands, except per share amounts)(unaudited) Three Months Ended June 30, Six Months Ended June 30, 2018 2017 2018 2017 Net loss$ (27,350) $ (8,184) $ (47,720) $ (14,708)Income tax expense (benefit) 126 (1,654) 297 (6,980)Loss before income taxes (27,224) (9,838) (47,423) (21,688)Adjustments to arrive at Adjusted net loss: Non-cash stock compensation expense 3,384 4,288 6,554 8,280 Charges related to litigation award and settlements - 4,450 740 4,450 Adjusted loss before income taxes (23,840) (1,100) (40,129) (8,958) Less: Adjusted income tax provision 262 (2,965) (1,828) (4,060)Adjusted net loss$ (24,102) $ 1,865 $ (38,301) $ (4,898) Adjusted net loss per diluted share$ (0.33) $ 0.03 $ (0.52) $ (0.07)
CONTACT:Corporate CommunicationsInvestor Relations Joe McGrathJackie Marcus or Chris Hodges INSYS TherapeuticsAlpha IR Group 480-500-3101312-445-2870 email@example.comINSY@alpha-ir.com